相关实验视频

Updated: Jan 10, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

基于血小板造影的XIII因子抑制剂查和诊断:一个病例报告

Jinsong Bai¹, Lianwei Ma², Jinghan Wang²

¹Department of Clinical Laboratory, Chengdu XinDu Hospital of Traditional Chinese Medicine, No 120, Xiangzhang Road, Xindu District, Chengdu, Sichuan 610500, PR China.

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis

|November 28, 2025

概括

这项研究通过使用Thromboelastography (TEG) 在年轻男性中确定获得的XIII因子 (FXIII) 缺乏. TEG参数,特别是最大幅度,与FXIII水平相关,使得FXIII抑制剂的新选方法成为可能.

科学领域:

血液学血液学血液学
临床凝血临床凝血
诊断方法诊断方法

背景情况:

获得的XIII因子 (FXIII) 缺乏症可以在正常的常规凝血测试中表现出来.
血栓形成显微镜 (TEG) 是一种粘弹性试验,提供全面的血液静止信息.
识别FXIII缺乏和抑制剂对于适当的患者管理至关重要.

研究的目的:

调查TEG在诊断获得的FXIII缺乏症中的有用性.
探索FXIII水平和TEG参数之间的相关性.
开发一种基于TEG的FXIII抑制剂查方法.

主要方法:

一个年轻男性的病例介绍,怀疑患有获得的FXIII缺乏症.
全血TEG分析以评估静血功能.
血混合研究以评估FXIII活性和抑制剂的存在.
在FXIII水平和TEG参数 (MA,角度) 之间的相关性分析.

主要成果:

患者呈现了正常的常规凝血测试,但TEG结果异常 (K延长,MA减少).
在XIII-A因子子单位水平和TEG最大幅度 (MA) 和角度之间观察到强烈的正相关性.
对与患者血清混合的血的TEG分析证实了FXIII抑制剂的存在.

结论:

血栓形成显微镜 (TEG) 可以检测与获得的XIII因子 (FXIII) 缺乏相关的异常.
TEG参数,特别是MA,是FXIII水平的敏感指标.
一种基于TEG的新查方法可以有效地识别FXIII抑制剂.

关键词:

流血出血流血出血血液凝固障碍血液凝固障碍这是一种XIII因子抑制剂.第十三因子缺乏症.在Thrombelastography中,我们可以使用Thrombelast.

更多相关视频

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization

Published on: June 4, 2020

Combined Near-infrared Fluorescent Imaging and Micro-computed Tomography for Directly Visualizing Cerebral Thromboemboli

Combined Near-infrared Fluorescent Imaging and Micro-computed Tomography for Directly Visualizing Cerebral Thromboemboli

Published on: September 25, 2016

相关概念视频

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...

Venous Thrombosis IV: Nursing Management

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...